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Early detection of tumors is today a major challenge and requires sensitive imaging
methodologies coupled with new efficient probes. In vivo optical bioluminescence
imaging has been widely used in the field of preclinical oncology to visualize tumors
and several cancer cell lines have been genetically modified to provide bioluminescence
signals. However, the light emitted by the majority of commonly used luciferases is
usually in the blue part of the visible spectrum, where tissue absorption is still very
high, making deep tissue imaging non-optimal, and calling for optimized optical imaging
methodologies. We have previously shown that red-shifting of bioluminescence signal
by Fluorescence Unbound Excitation from Luminescence (FUEL) is a mean to increase
bioluminescence signal sensitivity detection in vivo. Here, we applied FUEL to tumor
detection in two different subcutaneous tumor models: the auto-luminescent human
embryonic kidney (HEK293) cell line and the murine B16-F10 melanoma cell line
previously transfected with a plasmid encoding the Luc2 firefly luciferase. Tumor size and
bioluminescence were measured over time and tumor vascularization characterized. We
then locally injected near infrared emitting Quantum Dots (NIR QDs) in the tumor site and
observed a red-shifting of bioluminescence signal by (FUEL) indicating that FUEL could
be used to allow deeper tumor detection in mice.
Keywords: quantum dot (QD), tumor, in vivo optical imaging, bioluminescence, fluorescence
INTRODUCTION
Imaging of physiological and pathological processes benefits from sensitive methodologies (Wehrl
et al., 2014) and new imaging probes and methodologies are constantly evolving from the progress
in preclinical research and important insights that it has yielded. Preclinical and small-animal
imaging modalities allow longitudinal and multiparametric studies while reducing the number of
animals used in the studies and thus comply with ethical guidelines. They include MRI, SPECT,
and PET (Bernsen et al., 2014; Wehrl et al., 2014). Whilst MRI and nuclear imaging confer
high resolution and sensitivity, respectively, the cost of these scanners and their maintenance
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represent major limitations in their use. By contrast, optical
imaging is a widely used and low-cost methodology, also offering
high sensitivity but also high throughput (O’Farrell et al., 2013).
Bioluminescence imaging has been widely used in the
field of preclinical oncology. Several cell lines have been
genetically modified to provide both in vitro and in vivo
stable bioluminescence signals. In most cases, tumor cells are
modified to express the enzyme luciferase and then a suitable
substrate is added exogenously, which leads to the production
of light in presence of oxygen and ATP (Marques and Esteves
da Silva, 2009; O’Farrell et al., 2013). Recently, autonomous
bioluminescent mammalian cell lines have been developed.
These cell lines express both codon-optimized Photorhabdus
luminescens luciferases coding genes and associated genes
responsible for the production and recycling of aldehyde and
FMNH2 co-substrates required for light emission. As a direct
consequence, these cell lines do not require substrate addition to
be luminescent and autonomously and constantly produce light
(Close et al., 2010). In bioluminescence imaging, the photons
are produced by the reporter luciferase enzymes present in
the imaged subject (cells or animal). Because there is no non-
specific bioluminescence signal, and unlike fluorescence, there is
no need for an external excitation sources, the bioluminescence
light is highly specific and detected with low background
signals. However, the optical spectral region where common
luciferases maximally emit is between 480 and 620 nm, where
tissue absorption is maximum, highly limiting deep tissue
bioluminescence imaging (Close et al., 2011; O’Farrell et al.,
2013) while a range of wavelengths between 650 and 900 nm
is more suitable for in vivo imaging (Frangioni, 2003). Several
strategies have been developed in the last few years to overcome
this limitation by red-shifting the emission in the well-adapted
wavelength range where tissue absorption is minimal. One
of the strategies adopted is the Bioluminescence Resonance
Energy Transfer (BRET). BRET is a non-radiative process in
which energy is transferred from a bioluminescent donor to a
fluorescent acceptor that has been shown to be a powerful tool
to evaluate protein-protein interaction (Wu and Brand, 1994;
Pfleger and Eidne, 2006). Based on the principle of BRET, self-
illuminated quantum dots (QDs) have been designed (Xiong
et al., 2012). QDs are inorganic fluorescent nanocrystals that are
ideal candidate as BRET acceptor due to their broad absorbance
spectra, high absorbance cross sections, high fluorescence
quantum yield, and their large Stokes shift in the near infrared
(NIR) region (Michalet et al., 2005). In this context, carboxylate
QDs coupled with amide luciferase and even functionalized with
a RGD peptide have been developed for targeting in vivo cancer
cells (So et al., 2006; Yuan et al., 2015; Kamkaew et al., 2016;
Trapiella-Alfonso et al., 2018).
Recently, we reported Fluorescence by Unbound
Excitation from Luminescence (FUEL) as a mean to red-
shift bioluminescence emission without requiring extremely
close contact between donor and acceptor like in BRET. FUEL is
defined as a radiative transfer between a bioluminescent source
exciting nearby fluorophore (Dragavon et al., 2012; Holland
et al., 2014). We have hypothesized that FUEL could be a useful
tool for enhancing the detection of bioluminescent tumors
in preclinical imaging due to two main advantages. Firstly,
luciferase does not need to be grafted to the nanoparticles. This
would allow the use of smaller diameter nanoparticles, likely
to have superior pharmacokinetic properties in comparison to
coupled larger nanoparticles (Choi et al., 2007; Perrault et al.,
2009). Secondly, FUEL is a relevant mean to increase the signal
sensitivity in targeted tissue because QDs red emission is spatially
correlated with the tumor bioluminescence signal and results
to be a marker of proximity. However, this phenomenon would
be only applicable to preclinical tumor imaging, as it requires a
bioluminescent tumor cell line as source of excitation for QDs.
In this study, we focused on two different in vivo subcutaneous
bioluminescent tumor models to investigate the feasibility of
FUEL in detecting tumors. The first model was induced by
bioluminescent B16-F10 tumor cells expressing firefly luciferase
(Albanesi et al., 2012, 2013; Danciu et al., 2013). These cells will be
referred here as B16-Luc2. The second tumor model established
here was a bioluminescent HEK293 model, a human embryonic
kidney cell line expressing the lux operon from bacteria and will
hereon be referred as HEK-Lux. This cell type expresses both
the luciferase and enzymes required for the production of the
substrate, and therefore does not require further administration
of substrate to be autonomously bioluminescent (Close et al.,
2010). Using these two models, we present and quantify the first
in vivo FUEL experiments using near-infrared emitting quantum
dots to achieve a red-shifting emission of the subcutaneous
tumors in mice.
METHODS
Cell Lines Culture
The autobioluminescent HEK293 cells with the luxCDABE
operon (HEK-Lux) cells were kindly provided by 490 BioTech
(Tennessee, USA) (Xu et al., 2014). These cells were cultured
at 37◦C and 5% CO2 in DMEM with Glutamax and Pyruvate
(Life technologies) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Gibco), 1% of non-essential amino acids
(Sigma), 1% penicillin/streptomycin (Life technologies), and
100µg/mL G418 (Sigma). The experiments were performed with
cells at passage 20–22.
Non-autobioluminescent HEK293 cells were cultured in the
same medium as HEK-Lux cells, but in the absence of antibiotic
G418. At confluence, cells were rinsed with phosphate buffered
saline without Ca2+ and Mg2+ (PBS, Gibco) and harvested with
0.05% trypsin-EDTA (Gibco). Cells were used at passage 9.
The melanoma cell line B16-F10, expressing Luc2 (B16-Luc2)
was kindly provided by the group of Pierre Bruhns (Institut
Pasteur, Paris). The cells were cultured in RPMI 1640 with
glutamine and Hepes (Gibco) supplemented with 10% heat-
inactivated FBS and 1% penicillin/streptomycin. At maximum
50% of confluence, cells were rinsed with PBS and harvested with
0.05% trypsin-EDTA. The experiments were performed with cells
at passages between 6 and 16.
The emission spectra of the HEK-Lux and B16-Luc2 cells
were determined using 2 × 105 cells suspended in 0.1mL of
appropriated medium. One day prior to imaging, cells were
seeded in a 96-well clear bottom black plate (Nunc) and
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incubated overnight at 37◦C and 5% CO2. The medium was
gently removed from the wells and replaced with fresh medium
prior to image acquisition. For B16-Luc2 cells, the substrate D-
luciferin (Perkin Elmer) was added to the cells (150µg/mL in
0.01mL). Bioluminescence images were acquired with an IVIS
Spectrum system, using 20 nm bandpass emission filters and
OPEN mode (exposure time of 180 s for HEK-Lux cells and 30 s
for B16-Luc2 cells).
Mice and Ethics Statement
Female nude mice (Rj:NMRI-nu) (7 weeks-old) were obtained
from Janvier Laboratories (France). All protocols involving
animal experiments were approved and carried out in accordance
with the ethical guidelines of Institut Pasteur, Paris, and
approved by the Comité d’éthique de l’Institut Pasteur (CETEA
comité d’éthique en experimentation animale n◦89) under the
protocol license number: 2014-0055. The mice were housed
in the Biosafety Level 2+ animal facility of Institut Pasteur.
All mice had free access to food and water and were under
controlled light/dark cycle, temperature and humidity. Animals
were handled with regard for alleviation of suffering. Animals
were anesthetized using isoflurane, and euthanized with CO2.
Induction of Subcutaneous Tumors
HEK-Lux and Non-bioluminescent HEK Models
Each tumor was induced by subcutaneous (s.c.) administration
of 0.1mL of 5 × 106 cells (suspended in medium without FBS)
and basement membrane matrix growth factor reduced (matrigel
Corning), (25:75, v/v).
B16-Luc2 Model
Each tumor was induced by s.c. administration of 0.1mL
of 8 × 104 cells (suspended in medium without FBS)
and basement membrane matrix growth factor reduced
(matrigel, Corning), (20:80, v/v).
For all cell lines, culture medium was replaced with fresh
medium 1 day prior to the subcutaneous injection.
Two ventral tumors were induced in each mouse. The mice
were anesthetized with 2% isoflurane gas prior to the injection
of the tumor cells. Cells were first administered subcutaneously
on the left side and then on the right side of the mice. All the
results shown here represent measurements taken for the left
tumor of each mouse. Tumor growth was monitored by caliper
measurement and tumor volume determined as previously
described; volume= [(width/2)2 × length] (Ho et al., 2004).
Near Infra-Red (NIR) QDs
NIR QDs were synthesized as previously described (Bouccara
et al., 2014) and water-solubilized as described in Tasso et al.
(2015). Briefly, the size of the QDs is 3–5 nm in diameter
as measured by transmission electron microscopy (Bouccara
et al., 2014; Trapiella-Alfonso et al., 2018). After solubilization
with the zwitterionic copolymer, their hydrodynamic radius
is about 9 nm and their zeta potential is slightly negative
(typically ≈ −10mV) (Trapiella-Alfonso et al., 2018). Their
photoluminescence emission maximum is at 810 nm (Figure 1)
and their photoluminescence quantum yield at ∼15–25% when
FIGURE 1 | Characteristics of the materials used. (A) Table presenting the
features and properties of the two cell lines. (B) Normalized absorption
spectrum of the NIR QDs and normalized emission spectra of the NIR QDs,
the HEK-Lux cells, and the B16-Luc2 cells.
measured using indocyanine green as a standard (8 = 13%
in DMSO). These QDs have an excellent colloidal stability in
biological buffers and show no aggregation and limited non-
specific adsorption in albumin solutions and whole serum, even
after 48 h of incubation (Debayle et al., in review).
NIR QDs were diluted in PBS to provide the
desired concentration. Absorption and emission
spectra of a 0.1µM solution were determined using
IVIS Spectrum.
In vivo Bioluminescence and
Fluorescence Imaging
Bioluminescence and fluorescence imaging were performed
using an IVIS Spectrum system (Perkin Elmer). Unless specified
elsewhere, mice bearing the autobioluminescent HEK-Lux
tumors were anesthetized with 2% isoflurane gas and typically
imaged with (840 nm) and without emission filter (total light
output—open filter) for 300 s. Mice bearing the bioluminescent
B16-Luc2 tumors were intraperitoneally (i.p.) administered with
the substrate D-luciferin (0.75 mg/mouse, Perkin Elmer) 11min
prior to bioluminescence imaging. This time point was chosen
to allow a comparison between different mice and because
it corresponds to the D-luciferin peak bioavailability. Mice
were anesthetized with 2% isoflurane gas immediately after the
administration of D-luciferin and maintained under anesthesia
until the end of the image acquisition. Bioluminescence images
were acquired in the open mode or with the 840 nm filter for
180, 60, or 3 s, as specified in figures legends. Fluorescence images
were also acquired using IVIS Spectrum system (excitation filter
430 nm and emission filter 840 ± 20 nm). Living Image software
(Perkin Elmer) was used to define and analyze the light emission
in the regions of interest (ROIs).
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Angiosense 750EX
The fluorescent vascular agent Angiosense 750EX (Perkin
Elmer) was administered intravenously (i.v.) (2 nmol/0.1mL)
in mice bearing HEK-Lux or B16-Luc2 tumors, 22–30 or
7–9 days post-tumor cells injection, respectively. Mice were
anesthetized with 2% isoflurane gas prior to the image
acquisition. The vascularization of the tumors was evaluated 24 h
post-Angiosense 750EX administration using the IVIS Spectrum
system. Fluorescent images were acquired with 745 nm excitation
filter and 800 nm emission filter, with the auto option selected as
time of exposure.
NIR QDs
Fluorescent images using IVIS Spectrum were acquired prior and
after NIR QDs intratumoral administration in vivo with 0.1 s of
exposure time, and 430 and 840 nm as excitation and emission
filters, respectively.
Dextran- Fluorescein Isothiocyanate (FITC)
High molecular weight dextran-FITC (500 KMW, Molecular
Probes) was injected i.v. via the retro-orbital sinus (0.5
mg/0.1mL) in mice bearing HEK-Lux or B16-Luc2 tumors.
Harvested tumors were fixed in 4% paraformaldehyde (EMC)
for 3–5 h at room temperature, depending on the tumor
volume, followed by aldehydes quenching by 1 h incubation in
100mM glycine (Sigma-Aldrich). Tumors were then incubated
in 15% sucrose (Sigma-Aldrich) at 4◦C overnight and in
30% sucrose at 4◦C for ∼24 h before embedding in Shandon
Cryomatrix (Thermo Fischer) and freezing using isopentanol.
Fifty micrometer sections cut using cryostat (CM3050 S, Leica)
were stainedwithDAPI and imaged using an automated spinning
disk microscope CellVoyager1000 (Yokogawa Electrics, Japan).
The sections were left overnight at room temperature before
being stained with DAPI.
FUEL Experiments
In vitro FUEL
B16-Luc2, HEK-Lux, and HEK non-bioluminescent cells (2 ×
105, 0.1mL of appropriated medium) were seeded in a 96-well
clear bottom black plate (Nunc) 1 day prior to the experiment and
incubated at 37◦C and 5%CO2. On the day of the experiment, the
medium was removed and a fresh medium with or without NIR
QDs (450µM in 0.01mL) was added to the well. Each cell type
was cultured with the same medium used for the cell culture.
HEK non-bioluminescent cell type was used in this experiment
as a negative control for HEK-Lux cells. For B16-Luc2 cells,
the substrate D-luciferin was added to the wells (150µg/mL in
0.01mL), and the absence of the substrate in the well was used as
a negative control for this cell type. Bioluminescence images were
acquired with both 840 nm and open filter (exposure time of 300 s
for HEK cells and 180 s for B16-Luc2 cells). Fluorescence images
were also acquired (excitation 430 nm and emission 840 nm, 1 s
as exposure time).
Experiments With Mice Bearing B16-Luc2 Tumors
In order to evaluate the bioluminescence signal emitted at
840 nm before the administration of NIR QDs, D-luciferin (0.75
mg/mouse, i.p.) was administered in mice bearing B16-Luc2
tumors 11min prior to the image acquisition (180 s as exposure
time). After 1 h, bioluminescent images were acquired again to
determine the basal bioluminescent signal at 840 nm. Next, 0.5
nmol (0.04mL) NIR QDs were administered into the left tumor
and 0.04mL PBS into the right tumor. Fluorescence images
were acquired (excitation 430 nm/emission 840 nm, 0.1 s) prior
and post-NIR QDs intratumoral administration. D-luciferin
was then administered 11min prior to the bioluminescence
imaging acquisition with a 840 nm and open filter for 180 and
3 s, respectively.
Experiments were also performed to evaluate the possible
effect of NIR QDs without a bioluminescence source. For
this control, NIR QDs were injected in the left tumor and
PBS was injected in the right tumor of the mice, without
previous administration of D-luciferin. Both bioluminescence
and fluorescence images were acquired, using the same emission
and excitation filters and exposure time.
Experiments With Mice Bearing HEK-Lux Tumors
Bioluminescence images at 840 nm and open filter (300 s of
exposure time) were acquired prior and post-injection of 0.5
nmol (0.04mL) of NIR QDs in the left tumor and 0.04mL of
PBS in the right tumor of mice bearing the autobioluminescent
HEK-Lux tumors. Fluorescence images were acquired (excitation
430 nm and emission 840 nm, 0.1 s) prior and post-NIR QDs
intratumoral administration.
Statistics
The number of experimental repeats and animals used for each
experiment are noted in the figure legends. When compared,
B16-Luc2 and HEK-Lux tumors results were analyzed via Mann-
Whitney test or Student’s t-test after being assessed for normality
of sample distribution. For the statistical analyses, the results
from in vitro experiments were analyzed after normalization by
strictly standardized mean difference (SSMD) test as previously
described (Mellouk et al., 2014). Statistical analyses and graphs
plotting were performed using Prism 6.0 (GraphPad Software,
USA). P-values of ∗p < 0.05 and ∗∗p < 0.001 were used.
RESULTS
Characterization of Tumor Models Reveals
Marked Differences in Bioluminescence
Emission and Growth Dynamics but Shows
Similar Vascularization
In order to investigate the ability of FUEL to enhance the
detection of tumors in vivo, we used two distinct bioluminescent
preclinical subcutaneous tumor models in nude mice: murine
B16-Luc2 melanoma tumors previously described (Albanesi
et al., 2013) and the human HEK 293 tumor model, adapted from
the model described by Ho et al. (2004). Figure 1 summarizes the
different properties of the cell lines used and represent the optical
spectra of the QDs and bioluminescent tumor cell lines.
Firstly, we measured the emission spectrum for each of the
tumoral cell types on the imaging system used and observed an
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emission peak at 600 nm for B16-Luc2, while for HEK-Lux the
peak was at 500 nm (Figure 2A). It is noteworthy that the B16-
Luc2 cells emit a stronger bioluminescent signal when compared
to an equal number of HEK-Lux cells. B16-Luc2 cells also showed
higher in vivo proliferation than HEK-Lux cells. While 8 × 104
B16-Luc2 cells induced the formation of 400 mm3 tumors in 14
days, 5 × 106 HEK-Lux cells were necessary to induce similar
tumor sizes in more than 30 days (Figure 2B).
We also acquired bioluminescence images of tumors over
time, and observed that similar to the growth in tumor
volume, the bioluminescence signal intensity of B16-Luc2
tumors was detectable as early as 3 days post-injection and
increased over time to reach ∼108 photons emitted/s per
tumor on day 14 (Figures 3A,C). In contrast, HEK-Lux cells
produced significantly much less light with a different kinetic.
Although HEK-Lux cells emitted a detectable bioluminescence
signal immediately after the subcutaneous injection, this signal
disappeared on day 1. The signal stayed low until day 29,
when it started to increase again, reaching a maximum of 105
photons/s per tumor on day 38 (Figures 3B,C). Interestingly, the
signal increase correlated with the development of the tumor,
as assessed by an increase in tumor volume, suggesting that the
cells had a latency time before growing and emitting higher
bioluminescence signal. Altogether, these observations show that
the two tumor models have markedly different dynamics of the
growth curves and that the B16-Luc2 tumors emit 1,000 times
more light using an open filter for detection than the HEK-Lux.
We additionally investigated the vascularization of both
tumors using the vascular agent Angiosense 750EX. Fluorescence
images acquired 24 h post-Angiosense administration indicated
similar accumulation of the probe in both B16-Luc2 and HEK-
Lux-induced tumors (Figures 4A,B). Mice not bearing tumors
were used as control, and did not show fluorescence signal
in the upper abdomen. The fluorescence signal observed in
the lower abdomen, in both control and tumor-bearing mice,
is likely associated with the renal excretion of the probe. In
order to investigate the vascularization at microscopic levels,
we have administrated high molecular weight dextran labeled
with FITC i.v. Corroborating the results in vivo, histological
sections suggest that the vascularization is similar in both tumor
models (Figures 4C,D).
FUEL Enables Enhanced Detection
of Tumors
FUEL efficiency depends on the overlap between the emission
spectrum of the bioluminescent source and the excitation
spectrum of the acceptor fluorophore. NIR QDs have a broad
and continuous decreasing excitation spectrum from UV to
800 nm, as illustrated in Figure 1B. This spectrum suggests that
both B16-Luc2 (with an emission peak wavelength centered at
around 600 nm) and HEK-Lux bioluminescence signal (with
an emission peak wavelength centered at around 500 nm) are
suitable for the excitation of NIR QDs. Additionally, emission
spectrum indicates a maximum emission at around 840 nm.
Based on these spectra, we first investigated the presence of
FUEL with both B16-Luc2 and HEK-Lux in vitro. The incubation
of B16-Luc2 cells with NIR QDs significantly increased the
bioluminescence signal at 840 nm as compared to cells alone and
B16-Luc2 incubated with NIRQDs but in the absence D-luciferin
(Figure 5A). The presence of the NIR QDs in the specified
wells was confirmed by the fluorescence image (Figure 5A).
Normalized SSMD values classified the FUEL phenomenon
extremely strong as compared to the controls (Figures 5B,C).
HEK-Lux cells, which emit weaker bioluminescence signals, also
showed an increase in the intensity of bioluminescence at 840 nm
in the presence of NIR QDs. The statistical analyses using SSMD
normalization indicate a very strong difference between HEK-
Lux cells incubated with NIR QDs and controls (HEK-Lux cells
alone, and non-bioluminescent HEK cells incubated with NIR
QDs) (Figure 5B). It is important to mention that the scales for
B16-Luc2 and HEK-Lux are different due to the intensity of the
bioluminescence emitted by each cell types.
We next investigated the ability of FUEL to red-shift tumor
emission at the NIR QDs wavelength, enhancing the detection
of tumor at red range wavelengths. Mice bearing B16-Luc2
tumors were imaged after the i.p. administration of D-luciferin
to evaluate the background signal at 840 nm (–QD/+luciferin)
(Figure 6A). After the intratumoral injection of NIR QDs
(+QDs/+luciferin), we observed a drastic increase in the
bioluminescence signal at 840 nm, confirming the presence of
FUEL and its ability to enhance tumor detection at 840 nm by red
shifting the light emission (Figures 6A,C). Fluorescence imaging
confirmed the presence of NIR QDs in the tumor sites and
bioluminescence imaging in open filter shows that both right and
left tumors were bioluminescent upon the administration of D-
luciferin. No signal was observed in the absence of the substrate
(–QD/–luciferin and+QD/–luciferin).
FUEL efficiency was also investigated in HEK-Lux-
induced tumor model. Bioluminescence signal at 840 nm
post-intratumoral administration of NIR QDs was stronger
than pre-injection (–QD/HEK-Lux vs. +QD/HEK-Lux,
Figures 6B,C). NIR QDs administered into non-bioluminescent
HEK293 tumors showed bioluminescence signal statistically
similar to HEK-Lux tumors with NIR QD.
In summary, we have shown that both bioluminescent tumor
models undergo a red shifting in their emission via FUEL,
where the red-shifting emission strongly depends on the optical
emission properties of the tumors and the quantum yield of the
near-infrared emitting fluorescent probe.
DISCUSSION
The development of new techniques for detecting tumors in
an accurate and simple way is vital to support the search
for new therapies in oncology. In this study, we used two
different bioluminescent tumor models to demonstrate for the
first time, that the FUEL process can be used in vivo to red-shift
bioluminescence tumor emission and enhance the detection of
tumors in the infrared region.
Herein, we established two murine models of tumors to
investigate FUEL. One of the models was xenogeneic and made
use of human (HEK-Lux) cells, a constitutively bioluminescent
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FIGURE 2 | Characterization of emission spectra of B16-Luc2 and HEK-Lux cells and tumor growth curves. (A) Emission spectrum of B16-Luc2 and HEK-Lux cells.
Bioluminescence images were acquired from 500 to 840 nm for 30 s (B16-Luc2) or 180 s (HEK-Lux). Results are expressed as total flux (photons/s) in the ROI, n = 3.
(B) Tumor growth of B16-Luc2 (8 × 104, 0.1mL) and HEK-Lux (5 × 106) cells over time, following subcutaneous injection in nude mice on the right and left sides.
Results are representative of 4 independent experiments and represent the left tumor volume measured with a caliper, n = 5. Data shown are means ± SEM.
FIGURE 3 | Tumor bioluminescence signal evolution imaging over time. (A) B16-Luc2 cells (8 × 104, 0.1mL) were subcutaneously administered in nude mice. Mice
were imaged 1 day prior and 1, 3, 6, 9, and 14 days post-administration of B16-Luc2 cells, n = 5. (B) HEK-Lux cells (5 × 106, 0.1mL) were subcutaneously
adminstered in nude mice. Mice were imaged 6 days prior and 0, 1, 3, 8, 15, 22, 29, and 38 days post-administration of HEK-Lux cells, n = 6. (C) Bioluminescence
signal quantitation of B16-Luc2- and HEK-Lux-induced tumors. Red rectangles in 2A and 2B show the ROI used for quantification. Results express the total flux
(photons/s) in the ROI of the left tumor of the mice. These results are representative of 4 independent experiments.
cell type (Close et al., 2010). The second model was syngeneic,
induced by B16-Luc2, a murine melanoma cell type expressing
the enzyme luciferase frequently used in preclinical oncology
(Overwijk and Restifo, 2001). While B16-Luc2 tumor growth
and their bioluminescence signal showed the same profile, HEK-
Lux cells initially presented a high bioluminescence activity
immediately after the subcutaneous injection before showing a
marked decrease of this activity the following day.We believe that
these cells needed to adapt to the new environment, resulting in
undetectable light production, before propagating and forming
the solid tumor. After this latency period, the tumors reached
the maximal volume that corresponded with the second peak of
bioluminescence emission.
The developed models show different behaviors and were
used as a proof of concept of the feasibility of tumor detection
using FUEL in vivo, as well as to identify the critical conditions
allowing FUEL to occur. Each of the two models has advantages
and disadvantages with regard to FUEL applications. HEK-Lux
cells have the enormous advantage of being autobioluminescent
due to their constitutive expression of the bacterial lux operon
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FIGURE 4 | In vivo evaluation of tumor vascularization. (A) B16-Luc2 cells (8 × 104, 0.1mL), HEK-Lux (5 × 106, 0.1mL) were subcutaneously administered in nude
mice. Angiosense 750EX (2 nmol, 0.1mL) was intravenously administered between 7 and 9 days after B16-Luc2 injection or between 22 and 30 days post-HEK-Lux
cells injection Images were acquired 24 h after. (B) Fluorescence signal quantitation of Angiosense accumulation in B16-Luc2- and HEK-Lux-induced tumors. ROIs
were determined as shown in the first image of Figure 3A. Results express the difference between the average radiant efficiency in the ROI of the left tumor of the
mice with tumor and the arithmetic mean of the average radiant efficiency in the ROI of the left side in mice without tumor, (n = 4 control group and n = 5 for the
tumor bearing groups). (C) Visualization of tumor vascularization using high molecular weight dextran-FITC (500 KMW). Images correspond to a section in the tumors
at 50% depth. Contrast and brightness in both channels have been adjusted with an identical color scale across the four images. Scale bars: 100µm. (D) Area of
vascularization, defined as the percentage of the tumor area labeled by dextran at 0, 25, 50, 75, and 100% tumor depth. The area of vascularization was extracted
using an identical threshold over all images.
thus enabling convenient image acquisition without having
to consider the biodistribution kinetics of exogenously added
substrate in vitro or in vivo (Close et al., 2010) unlike for the
B16-Luc2 cells (Albanesi et al., 2012). This required substrate
injection is an important limitation since the time between
substrate injection and imaging needs to be strictly controlled
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FIGURE 5 | In vitro investigation of FUEL with NIR QDs. (A) Bioluminescence (840 nm, exposure time of 60 s (B16-Luc 2 cells) and 180 s (HEK-Lux cells), as well as
fluorescence images (excitation 430 nm, emission 840 nm, and exposure time of 1 s). (B) Quantitation of bioluminescence signal emitted at 840 nm. Results are
expressed as normalized SSMD values for B16-Luc2 cells (B16-Luc2 cells + D-luciferin used as control) or (C) HEK-Lux (or non-bioluminescent HEK used as control).
n = 8 (except for HEK-Lux + QD – n = 6).
to obtain quantitative reproducible and comparable data, mainly
when acquiring images using different emission filters before and
after the injection of NIR QDs. In addition, melanin production
by the B16-Luc2 cells might be a concern for this type of
imaging. However, we observed thatmelanin expression becomes
significant only 2 weeks after subcutaneous injection, after we
performed our experiments, and that these cells are indeed suited
for FUEL imaging (Figure 6).
FUEL is a phenomenon that allows the red shifting of
the light, enhancing the detection of bioluminescent tumors
because of the reduction of tissue absorption and scattering of
blue/green light. One of the requirements for effective FUEL is
that the fluorophore should have a large Stokes shift, determining
the requirement of an ideal bioluminescent emitting source
at ∼500 nm (Dragavon et al., 2012; Holland et al., 2014). In
this context, the wavelength of the maximal bioluminescence
emission peak of HEK-Lux cells would be another advantage
over B16-Luc2 cells regarding FUEL. Indeed, HEK-Lux cells
emit luminescence at a maximum peak of 490 nm (Close et al.,
2010). By contrast, B16-Luc2 cells have a maximum emission
peak at 600 nm. In our case, we were still able to observe
FUEL with B16-Luc2 because we used NIR QDs, which have
a large absorption range. Furthermore, B16-Luc2 cells showed
much stronger bioluminescence signal intensity in comparison
to HEK-Lux cells, requiring shorter exposure times during
imaging and overall higher FUEL efficiency. Our results show
that even if HEK-Lux cells have a more appropriate maximum
emission wavelength to excite NIR QDs than B16-Luc cells, due
to their lower luminescence intensity, the red-shifting emission
is not optimal. Indeed, if we focus on the maximum emission
wavelength of both cell types, 500 and 600 nm for HEK-Lux
cells and B16-Luc2 cells, respectively, NIR QDs absorb 4 times
less at 600 nm than at 500 nm (Figure 1B). However, for an
identical number of cells, at their maximum wavelength, the
B16-Luc2 cells are about 800 times brighter at 600 nm than
the HEK-Lux cells are at 500 nm (when the same number of
cells are compared). At 500 nm, B16-Luc2 emission is still 14
times higher than HEK-Lux cells emission (Figure 2A). These
results highlight the fact that FUEL efficiency is controlled by
a combination of both luminescence spectrum and intensity as
well as acceptor absorbance properties. Having theoretical model
of the interactions governing FUEL in vivo would help design
such best possible combinations. Nevertheless, NIR QDs have
many advantages for FUEL applications; namely high excitation
coefficient and photoluminescence quantum yield. Moreover,
this specific type of NIRQD has been shown to provide a lower in
vivo toxicity compared to classical NIR QDs mainly because they
are not composed of heavy metals (Pons et al., 2010). In addition,
FUEL efficiency also depends on the imaging conditions. Indeed,
the emission filters used in this study have a narrow 20 nm
bandwidth, which limits the imaging of the red-shifted emission
photons. Using larger emission filter bandwidth or long pass
emission filter should significantly improve the FUEL efficiency.
Our results suggest that FUEL enables red shifting emission
of bioluminescent tumors to the near infrared region, that is a
major advantage for deep and metastatic tumor detection. As an
optical method, FUEL has the significant advantage of requiring
affordable imaging systems and facilities (O’Farrell et al., 2013)
that are extremely valuable in preclinical research. However, the
experimental conditions of FUEL phenomenon for detecting
tumors warrants some improvement and characterization to
be fully suitable for enhanced detection of deeper tumors in
vivo. Several factors mainly need to be taken into account: the
biodistribution of the QDs within the xenograft, considering
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 8 April 2019 | Volume 7 | Article 73
Sônego et al. FUEL Imaging in Tumors
FIGURE 6 | Continued
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FIGURE 6 | In vivo evaluation of FUEL. Bioluminescence imaging at 840 nm of B16-Luc2 (A) or HEK-Lux (B) tumors prior (left image) or after quantum dots injection
in the right tumor (2nd image left). Fluorescence images and bioluminescence in open mode are shown on the right. 840 nm bioluminescene images of control without
luciferase for B16-Luc2 Cells (A) or non-bioluminescent HEK cells (B) are shown in the second row. (C) Quantitation of FUEL phenomenon. ROIs were determined as
shown in the image of Figure 5A. Results express the difference between total flux (photons/s) in the ROI of the left tumor of the mice post-NIR QDs injection and prior
to the NIR QDs injection, n = 3 (negative control groups), n = 6 (B16-Luc2), and n = 4 (HEK-Lux). p < 0.05 was considered as significant: *p < 0.05 and **p < 0.001.
the tumor heterogeneity, and the fact that the tumor micro-
environment could affect both luciferase enzymatic efficiency
and fluorophore quantum yield, and consequently overall FUEL
efficiency. The enhanced permeability retention (EPR) effect
exhibited by tumors as a result of leaky vasculature, could
favor the retention of nanoparticles (Blanco et al., 2015). An
effective EPR effect is strongly dependent on the size of the
nanoparticles, their surface chemistry and the type of tumor.
For instance, the accumulation and distribution of micelles
of various sizes was not substantially affected by the size
in a colon adenocarcinoma (C26) model, while micelles size
prove to be important in a human pancreatic adenocarcinoma
(BxPC3) (Cabral et al., 2011). Positively charged nanoparticles
have been shown to have shorter circulation half-life, but
enhanced internalization due to their adsorptive interaction
with the cell membrane. Interestingly, Yuan et al. demonstrated
the enhanced tumoral retention of zwitterionic nanoparticles
with switchable charge based on environmental stimulus (Yuan
et al., 2012; Blanco et al., 2015). The i.v. injection of 0.5
nmol of NIR QDs in our models did not result in NIR
QDs tumor detection via EPR effect under our experimental
conditions (Supplementary Figure 1). This absence of EPR effect
is unlikely to be due to QDs aggregation or agglomeration
as these QDs have been shown to be stable and disperse in
serum (Debayle et al., in review). One alternative to enhance
the tumor targeting is to couple the nanoparticles to antibodies
or peptides. For instance, RGD (Arg-Gly-Asp) is a triple-
peptide motif with binding affinity to αvβ3 integrin which
is highly expressed in neovasculature and many tumor lines
(Martelli et al., 2016). Optical and nuclear imaging probes
coupled to RGD have been shown to target tumors and
improve their visualization in mice (Li et al., 2006). Likewise,
Trapiella-Alfonso et al. observed a higher tumor uptake of
RGD-NIR QDs 15–30min after probe injection, as well as,
similarly to us, a lower long lasting fluorescence with non-
functionalized NIR QDs (Trapiella-Alfonso et al., 2018). In
addition, NIR QDs or iron oxides nanoparticles coupled to
anti-HER2 showed high specificity in targeting subcutaneous
ovarian and prostate xenografts (Gao et al., 2011). The signal
localization and intensity hence depend on several physiological
parameters including mainly the tumor vascularization and
its environment. It would be interesting to investigate in
more details what are the critical parameters enabling QDs
tumor uptake with different types of functionalization as
well as different tumor models providing different patterns
of vascularization.
To summarize and conclude, we have shown the development
of two different tumor models and FUEL ability to red shifting
their emission. With further improvements, this optical method
could offer an attractive alternative for detecting smaller and
deeper tumors in preclinical models.
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